Harout Semerjian: Announcement of initial findings from our Phase 1a study of GMI-1687

Harout Semerjian, President and CEO at GlycoMimetics, shared a post by GlycoMimetics on LinkedIn:

“As we kick off 2024, I am encouraged by our significant progress and inspired by the opportunity before GlycoMimetics in 2024.

Thanks to our team’s partnership with investigators, regulators, and patients, we are on track to report topline results from our Phase 3 study of uproleselan in R/R AML by end of Q2, and further advance our pipeline with today’s announcement of initial findings from our Phase 1a study of GMI-1687.
Hope to see many of you at JPM next week!”

Quoting GlycoMimetics’s post:

“GlycoMimetics today announced initial safety and pharmacokinetic results from a Phase 1a healthy volunteer study of e-selectin antagonist GMI-1687. Learn more.”

Source: Harout Semerjian/LinkedIn and GlycoMimetics/LinkedIn